Arthritis and Rheumatism Center INC., a Medical Corporation

Arthritis and Rheumatism Center INC., a Medical Corporation was paid $26.71M by Medicaid between Jan 2018 and Oct 2024, across 15 billing codes. Its largest line is J0717, Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) — 61% of everything it billed.

Compared with peers

Next to other Rheumatology Physician providers in California

Rank by total paid#3 of 147

Median peer was paid$43K

This provider vs. median616×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	742	$411K
2019	3,639	$3.64M
2020	4,250	$4.49M
2021	4,769	$5.20M
2022	5,387	$4.96M
2023	5,670	$4.79M
2024incomplete	4,394	$3.21M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	61%	4,356	3,642	$16.19M
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	34%	2,818	2,496	$9.03M
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	2.3%	204	189	$601K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	<1%	5,939	5,808	$204K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	3,824	3,465	$200K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	4,138	3,457	$137K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	<1%	50	49	$112K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	<1%	1,623	1,619	$105K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	<1%	3,560	3,523	$79K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	1,062	968	$20K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	470	429	$9K
99203	Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity	<1%	118	118	$6K

3 more codes

96401		<1%	418	$6K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	226	$4K
20610		<1%	45	$1K

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCHAHAL, ANUPAM (AUTHORIZED OFFICIAL)